Alto Neuroscience (NYSE:ANRO) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen downgraded shares of Alto Neuroscience (NYSE:ANRO) from a sell rating to a strong sell rating in a report released on Saturday morning.

Several other brokerages have also weighed in on ANRO. Wolfe Research started coverage on Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating for the company. Robert W. Baird lowered their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Finally, Zacks Research downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO opened at $27.09 on Friday. The stock has a market cap of $950.76 million, a price-to-earnings ratio of -11.20 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. Alto Neuroscience has a 12 month low of $3.00 and a 12 month high of $28.85. The stock’s 50 day moving average price is $24.11 and its 200 day moving average price is $21.90.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Equities research analysts anticipate that Alto Neuroscience will post -3.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors have recently bought and sold shares of ANRO. Invesco Ltd. purchased a new stake in Alto Neuroscience during the first quarter valued at about $67,000. AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience in the first quarter worth about $52,000. Marshall Wace LLP increased its position in shares of Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after acquiring an additional 84,417 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Alto Neuroscience in the second quarter worth approximately $240,000. Finally, Bridgeway Capital Management LLC raised its holdings in shares of Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.